肝脏或胆道疾病患者血清中胆汁糖蛋白（BGP I）水平升高。
Elevated serum levels of a biliary glycoprotein (BGP I) in patients with liver or biliary tract disease.
作者信息
Svenberg T, Wahren B, Hammarström S
出版信息
Clin Exp Immunol. 1979 May;36(2):317-25.
Human hepatic bile contains a glycoprotein (biliary glycoprotein I, BGP I) which cross-reacts with the carcinoembryonic antigen (CEA). A radioimmunoassay for BGP I was developed. The interference of CEA or 'non-specific cross-reacting antigen' (NCA) in the assay was small. The serum levels of BGP I were determined in healthy subjects, in patients with hepato-biliary diseases and in patients with various infectious or inflammatory disorders. Healthy individuals, including pregnant women, had a serum BGP I concentration of about 0.5-1 mg/l. Diseases of the liver or biliary tract (e.g. hepatitis A or B, cytomegalovirus hepatitis, obstructive jaundice or primary biliary cirrhosis) were associated with elevated serum levels of BGP I, as opposed to infectious diseases not affecting the liver mostly showing values within the normal range. Raised levels of serum BGP I activity may reflect biliary obstruction as a result of interference with normal BGP I secretion to the bile.
人肝胆汁含有一种与癌胚抗原（CEA）发生交叉反应的糖蛋白（胆汁糖蛋白I，BGP I）。已开发出一种针对BGP I的放射免疫测定法。CEA或“非特异性交叉反应抗原”（NCA）在该测定法中的干扰较小。对健康受试者、肝胆疾病患者以及各种感染性或炎症性疾病患者的血清BGP I水平进行了测定。包括孕妇在内的健康个体血清BGP I浓度约为0.5 - 1毫克/升。肝脏或胆道疾病（如甲型或乙型肝炎、巨细胞病毒性肝炎、梗阻性黄疸或原发性胆汁性肝硬化）与血清BGP I水平升高有关，而未影响肝脏的传染病大多显示值在正常范围内。血清BGP I活性水平升高可能反映由于正常BGP I向胆汁分泌受到干扰而导致的胆道梗阻。
Zotero 插件